Activ-2 Results: Retatrutide Phase 3 Preview

Last updated: April 2026

Disclaimer: This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting any treatment.

Affiliate Disclosure: We may earn a commission when you purchase through our links. This does not affect our editorial independence.

Quick Answer

Retatrutide is a triple agonist from Lilly, showing significant reductions in A1C and weight in its first Phase 3 trial for type 2 diabetes.
The drug reduced A1C and weight in participants with type 2 diabetes.
Lilly is also developing orforglipron, an oral GLP-1, which helped people maintain weight loss after switching from injectable incretins, with participants maintaining all but 0.9 kg of their previously achieved weight loss on average when switching from Wegovy to orforglipron.
Orforglipron delivered an average weight loss of up to 27.3 lbs in one Phase 3 trial for adults with obesity.

Eli Lilly and Company's investigational drug, retatrutide, is making headlines as a promising new treatment, particularly for people living with type 2 diabetes and those with obesity or who are overweight. This medication, known as a triple agonist, has shown significant results in its initial Phase 3 trials. Specifically, retatrutide demonstrated substantial reductions in A1C levels, a key measure of blood sugar control, and also led to meaningful weight loss in participants with type 2 diabetes during its first Phase 3 trial. These findings highlight its potential to address multiple health challenges simultaneously. The development of retatrutide is part of Lilly's broader effort to expand treatment options, alongside other innovative medications like orforglipron, an oral GLP-1 that has also shown impressive results, including an average weight loss of up to 27.3 lbs in adults with obesity in one pivotal Phase 3 trial. We are closely watching these developments as they could change how we approach the management of these conditions.

What is Retatrutide?

Retatrutide, identified by its research code LY3437943, is an exciting new medication developed by Eli Lilly and Company. It belongs to a new class of drugs known as triple agonists. This means it works by activating three different hormone receptors in the body: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors. By targeting these multiple pathways, retatrutide aims to provide comprehensive benefits for managing blood sugar and body weight. Our understanding of these receptors suggests that stimulating them together can lead to enhanced effects compared to targeting just one or two.

The Science Behind Triple Agonism

The human body uses several hormones to regulate blood sugar, appetite, and metabolism. GLP-1 and GIP are "incretin" hormones that help the pancreas release insulin when blood sugar is high. They also slow down digestion and reduce appetite. Glucagon, on the other hand, typically raises blood sugar. However, activating the glucagon receptor in certain ways, especially in combination with GLP-1 and GIP, can lead to increased energy expenditure and further weight loss. Retatrutide's unique triple action is designed to leverage these synergistic effects, offering a powerful approach to both glycemic control and weight management. This multi-pronged attack on metabolic dysregulation is what sets triple agonists apart from earlier generations of GLP-1 medications, which typically targeted only one or two of these pathways. The goal is to achieve more profound and sustained improvements in health outcomes for patients.

Development and Clinical Trials

Eli Lilly and Company has been systematically studying retatrutide through a series of rigorous clinical trials. These trials are essential for evaluating the drug's safety, effectiveness, and optimal dosing. The development journey began with early-phase studies to establish preliminary safety and efficacy, moving into larger, more extensive Phase 3 trials. These later-stage trials involve a significant number of participants and are designed to confirm the drug's benefits against established treatments or placebos. The data collected from these studies will ultimately support regulatory submissions for approval, making the medication available to the public. The company's commitment to thorough research ensures that new medications like retatrutide are well-understood before they reach patients. We monitor these trials closely to understand the full scope of retatrutide's potential.

Potential Applications of Retatrutide

Retatrutide is being investigated for a range of metabolic conditions. Its primary focus areas include the treatment of type 2 diabetes and the management of obesity or overweight. For individuals with type 2 diabetes, the drug's ability to lower A1C and promote weight loss addresses two critical aspects of the disease. For those struggling with obesity or being overweight, retatrutide offers a potential new tool for significant weight reduction, which can in turn improve numerous obesity-related health complications. The comprehensive nature of its action suggests it could become a versatile option for healthcare providers. We believe that a medication offering both strong glycemic control and substantial weight loss could fill an important gap in current treatment paradigms. The ongoing studies aim to fully characterize these benefits and identify the specific patient populations who would gain the most from this novel therapy.

What are the latest Phase 3 trial results for type 2 diabetes?

Lilly announced significant reductions in A1C and weight in the first Phase 3 trial for retatrutide in people with type 2 diabetes. We track all of it in our complete retatrutide evidence review. This marks a major milestone in the development of this triple agonist, indicating its strong potential for managing both blood sugar and body weight effectively. The trial results, as reported by Eli Lilly and Company, showed that retatrutide demonstrated significant reductions in A1C and weight in its first Phase 3 trial for treatment of type 2 diabetes. These findings underscore the drug's dual action in addressing key metabolic challenges faced by individuals with type 2 diabetes.

Detailed Findings on A1C Reduction

The reduction in A1C levels is a crucial indicator of improved blood sugar control over several months. For people with type 2 diabetes, lowering A1C can significantly reduce the risk of long-term complications such, as heart disease, kidney disease, and nerve damage. The reported significant A1C reductions observed with retatrutide suggest that the drug effectively helps the body manage glucose levels, potentially through its multiple receptor activation. This is a primary goal in diabetes treatment, and achieving such results in a Phase 3 trial is a strong signal of efficacy. When we compare this to other available treatments, the magnitude of A1C lowering will be a key factor in determining its place in therapy. We are eager to see the full published data to understand the specific percentages of A1C reduction at different doses.

Impact on Body Weight in Diabetes Patients

Beyond blood sugar control, retatrutide also achieved significant weight reductions in participants with type 2 diabetes. Weight management is often a co-existing challenge for individuals with type 2 diabetes, and weight loss can profoundly improve insulin sensitivity and overall metabolic health. The ability of retatrutide to reduce both A1C and body weight simultaneously makes it a particularly attractive option. Many diabetes medications can sometimes lead to weight gain, so a treatment that actively promotes weight loss represents a substantial advantage. This dual benefit could simplify treatment regimens and improve patient adherence by addressing multiple concerns with a single medication. Losing weight can also alleviate pressure on joints, improve sleep apnea, and boost quality of life, further enhancing the drug's value.

Significance of the First Phase 3 Trial

The successful completion of the first Phase 3 trial with positive results is a critical step in the regulatory approval process. Phase 3 trials are large-scale studies designed to confirm the efficacy and safety of an investigational drug in a diverse patient population. The fact that retatrutide achieved "significant reductions" in both A1C and weight in this pivotal trial means it met its primary endpoints. This provides strong evidence that the drug performs as intended and offers meaningful benefits to patients. These early announcements typically precede the full publication of detailed data, which will include specific numerical outcomes, adverse event profiles, and subgroup analyses. We anticipate that these forthcoming publications will offer a more complete picture of retatrutide's performance and its potential role in clinical practice. The news release from Eli Lilly and Company is often the first public disclosure of such important trial outcomes, setting the stage for deeper scientific review. Lilly News Release on Retatrutide Phase 3 Results provides further context on these initial findings. The excitement surrounding these results stems from the potential for a new, highly effective tool in the battle against type 2 diabetes and its associated complications.

How does Retatrutide compare to other GLP-1 medications?

Retatrutide stands out from many existing GLP-1 medications because it is a triple agonist, meaning it targets three different hormone receptors: GLP-1, GIP, and glucagon. Most currently available GLP-1 medications are either single agonists, targeting only GLP-1 receptors (like semaglutide, known as Ozempic or Wegovy), or dual agonists, targeting GLP-1 and GIP receptors (like tirzepatide, known as Mounjaro or Zepbound). This broader action of retatrutide may offer enhanced benefits for both weight loss and glycemic control, potentially leading to more pronounced effects. The mechanism of action is a critical differentiator when we consider the landscape of incretin-based therapies.

The Evolution of Incretin Therapies

The field of incretin-based therapies has evolved significantly over the past two decades. Initially, drugs focused solely on the GLP-1 pathway, which proved effective in lowering blood sugar and promoting some weight loss. Then came dual agonists, which added GIP receptor activation, showing even greater efficacy in both areas. Retatrutide represents the next generation, incorporating glucagon receptor agonism into the mix. This progression reflects a deeper understanding of metabolic physiology and how multiple hormonal pathways interact to influence glucose homeostasis and energy balance. By activating the glucagon receptor in combination with GLP-1 and GIP, retatrutide may stimulate energy expenditure, potentially contributing to greater weight reduction than what is seen with single or dual agonists. This is a complex interplay, where the specific balance of activation across the three receptors is key to achieving optimal therapeutic outcomes without unwanted side effects.

Potential for Enhanced Efficacy

The hypothesis behind triple agonism is that by engaging more pathways involved in metabolism and appetite regulation, a drug can achieve superior results. While specific comparative data from head-to-head trials against semaglutide or tirzepatide are still emerging for retatrutide, the initial Phase 3 results for type 2 diabetes are very promising. The significant reductions in A1C and weight observed suggest that its multi-target approach is effective. The added glucagon component is thought to contribute to a metabolic boost, helping the body burn more calories and further aiding in weight loss, beyond the appetite suppression and insulin-sensitizing effects of GLP-1 and GIP. This comprehensive approach could potentially offer a new benchmark for efficacy in both diabetes and obesity treatment. We are closely watching for more detailed comparative data as trials progress to fully understand the extent of these enhanced benefits.

Safety and Tolerability Profile

As with any new medication, the safety and tolerability profile of retatrutide will be crucial for its widespread adoption. While the initial news releases focus on efficacy, detailed safety data from the Phase 3 trials will be rigorously reviewed. Common side effects for GLP-1 and dual agonists often include gastrointestinal issues like nausea, vomiting, diarrhea, and constipation. It will be important to see if the addition of glucagon agonism alters this profile or introduces new considerations. The balance between enhanced efficacy and a manageable side effect profile is always a key factor in drug development. Lilly's extensive experience with incretin mimetics suggests a careful approach to dose titration and patient monitoring will be central to its clinical use. The ongoing trials are designed to fully characterize these aspects, providing a complete picture of retatrutide's risk-benefit ratio. Understanding these details will help clinicians determine which patients might benefit most from this triple agonist compared to other options.

Future Role in Treatment Paradigms

Given its novel mechanism of action and promising early results, retatrutide could play a significant role in future treatment paradigms for type 2 diabetes and obesity. For patients who may not achieve their treatment goals with existing single or dual agonists, a triple agonist could offer a more potent alternative. It might also be considered as a first-line therapy for individuals with severe obesity or poorly controlled diabetes who require substantial improvements in both glycemic control and weight. The availability of multiple effective medications with different mechanisms will allow for more personalized treatment approaches. As more data becomes available, we will be able to better understand how retatrutide fits into the broader landscape of GLP-1 and related therapies, potentially offering an even more powerful tool for clinicians and patients alike.

What is the status of Retatrutide for obesity or overweight?

A study of retatrutide (LY3437943) in participants who have obesity or are overweight is currently active. This ongoing trial is a crucial part of understanding retatrutide's full potential beyond type 2 diabetes. The study is identified as NCT05929066 on ClinicalTrials.gov, a public database of clinical studies worldwide. This trial is specifically designed to evaluate the safety and efficacy of retatrutide in this population, focusing on its ability to induce and sustain weight loss.

Details of the Obesity/Overweight Trial (NCT05929066)

The study NCT05929066 is titled "A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight." This trial is a pivotal part of Lilly's development program for retatrutide, aiming to gather comprehensive data on its effects in individuals whose primary health challenge is excess body weight. ClinicalTrials.gov provides detailed information about this study, including its design, eligibility criteria, and primary and secondary outcome measures. These details are important for researchers and the public to understand the scope and objectives of the trial. The trial is structured to provide robust evidence that will support potential regulatory approval for weight management indications. We regularly check these databases for updates, as they are the official record of ongoing research. Retatrutide Study Details on ClinicalTrials.gov offers a direct link to the full study record.

Eligibility and Study Design

Clinical trials for obesity or overweight typically enroll participants based on specific criteria, such as a Body Mass Index (BMI) above a certain threshold, sometimes with co-existing weight-related conditions. The design of NCT05929066 likely involves multiple treatment arms, with participants receiving different doses of retatrutide or a placebo. This randomized, controlled design is the gold standard for clinical research, ensuring that any observed effects can be attributed to the drug itself. The study will monitor various endpoints, including changes in body weight, body composition, and other metabolic parameters over a defined period. Long-term follow-up is also common to assess the durability of weight loss and the long-term safety profile. Understanding the specifics of the study design helps us interpret the eventual results with greater accuracy and context.

Anticipated Outcomes and Impact

Given the promising results seen in the type 2 diabetes trial, we anticipate that the obesity/overweight trial for retatrutide will also demonstrate significant weight loss. The triple agonist mechanism, with its combined effects on appetite suppression, improved glucose metabolism, and potential energy expenditure, is particularly well-suited for addressing obesity. If successful, retatrutide could offer a powerful new option for individuals struggling with obesity, a condition that affects millions worldwide and is linked to numerous health complications. Substantial weight loss can lead to improvements in conditions such as hypertension, dyslipidemia, sleep apnea, and joint pain, significantly enhancing quality of life and reducing healthcare burdens. The potential for such a comprehensive impact makes this trial highly anticipated.

The Broader Context of Lilly's Weight Management Pipeline

Lilly is deeply invested in developing innovative treatments for obesity, recognizing the significant unmet medical need. Retatrutide is a key component of this pipeline, but it is not the only one. The company is also advancing other medications, including orforglipron, an oral GLP-1 receptor agonist, which we will discuss further. This multi-product strategy ensures that a range of options, including both injectable and oral formulations, with different mechanisms of action, may become available to patients. This comprehensive approach reflects a commitment to offering personalized solutions for weight management, acknowledging that different individuals may respond better to different therapies. The availability of multiple effective treatments is crucial for addressing the diverse needs of the patient population. We continue to track all of Lilly's clinical trials, including Lilly Clinical Trials for Retatrutide, which provides a broader overview of their research efforts.

What is Orforglipron, and how does it relate to Retatrutide?

Orforglipron is another innovative medication from Eli Lilly and Company, but it is distinct from retatrutide in several key ways. While both are being developed for weight loss and metabolic health, orforglipron is an oral GLP-1 receptor agonist, whereas retatrutide is an injectable triple agonist. This oral formulation makes orforglipron a potentially more convenient option for many patients who prefer pills over injections. Orforglipron has also shown promising results in its own Phase 3 trials for weight loss, highlighting Lilly's diverse pipeline in this therapeutic area.

Mechanism of Action and Formulation

Orforglipron works by activating the GLP-1 receptor, similar to the GLP-1 component of retatrutide. However, it is a single agonist, meaning it does not activate the GIP or glucagon receptors like retatrutide does. The most significant difference is its oral administration. Being an oral small-molecule GLP-1 receptor agonist, orforglipron offers a convenient alternative to injectable GLP-1 medications. This oral route of administration could significantly improve patient adherence and access to treatment, especially for those who are needle-averse or find injections cumbersome. The development of effective oral GLP-1s is a major advancement in the field of obesity and diabetes management. According to Sean Wharton et al., orforglipron is an oral small-molecule GLP-1 receptor agonist for obesity treatment, as published in N Engl J Med. 2025. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment - PubMed.

Phase 3 Trial Results for Orforglipron

Orforglipron has demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trials. These trials have shown its effectiveness in both initial weight loss and weight maintenance. In one pivotal Phase 3 trial, orforglipron delivered weight loss of up to an average of 27.3 lbs in adults with obesity. This level of weight loss is substantial and comparable to some of the most effective injectable GLP-1s currently available. The results highlight its potential as a powerful tool for weight management. Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity.

Weight Maintenance After Switching from Injectables

One particularly innovative Phase 3 trial, ATTAIN-MAINTAIN, explored orforglipron's ability to help people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy. This was a first-of-its-kind study. In ATTAIN-MAINTAIN, orforglipron achieved the primary and all key secondary endpoints for weight maintenance versus placebo at 52 weeks following weight loss on Wegovy or Zepbound. The results were highly encouraging: participants who switched to orforglipron from Wegovy maintained all but 0.9 kg of their previously achieved weight loss on average. This demonstrates that orforglipron can be an effective option for sustaining weight loss, even when transitioning from other potent injectable medications. This flexibility in treatment options could be very beneficial for patients seeking long-term weight management solutions. Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial.

Regulatory Status

Lilly has recognized the strong potential of orforglipron and has taken steps toward making it available to patients. The company has submitted orforglipron to the U.S. Food and Drug Administration (FDA) for the treatment of obesity. This submission indicates that Lilly believes the clinical data is robust enough to support approval. The FDA review process will involve a thorough examination of all submitted efficacy and safety data before a decision is made. The potential approval of an effective oral GLP-1 could represent a significant shift in how obesity is treated, offering a more accessible and less invasive option for many. Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial.

Complementary Roles in Lilly's Portfolio

While retatrutide and orforglipron are distinct, they both contribute to Lilly's comprehensive strategy in metabolic health. Retatrutide, as a triple agonist, might offer maximal efficacy for individuals needing the most aggressive treatment for diabetes and obesity. Orforglipron, as an oral GLP-1, could provide a highly effective and convenient option for a broad range of patients, including those seeking an alternative to injections or those needing to maintain weight loss. These two medications are not necessarily in competition but rather serve as complementary tools, expanding the arsenal available to healthcare providers and patients. This diversified approach ensures that Lilly is addressing various patient needs and preferences within the complex landscape of metabolic diseases.

When can we expect more data on Retatrutide?

Eli Lilly and Company continues to conduct extensive clinical trials for retatrutide, and we can anticipate more detailed results from these ongoing Phase 3 trials in the future. The initial announcements about significant reductions in A1C and weight in type 2 diabetes patients are just the first glimpse. Full scientific publications and presentations at major medical conferences typically follow these preliminary disclosures, providing a deeper dive into the data. We will provide updates as new data becomes publicly available from authoritative sources.

The Timeline of Clinical Trial Data Release

Clinical trial data release typically follows a structured timeline. After a company announces top-line results, such as the initial positive findings for retatrutide in type 2 diabetes, the next step is usually the presentation of more comprehensive data at scientific meetings. These presentations often include detailed efficacy numbers, a full breakdown of adverse events, and analyses across different patient subgroups. Following presentations, the full results are often submitted for publication in peer-reviewed medical journals. This rigorous process ensures that the scientific community can thoroughly review and validate the findings. The time between initial announcements and full publications can vary, but it is an essential part of establishing the drug's profile. We track these stages closely to bring you the most complete and accurate information.

What to Expect in Future Data Releases

Future data releases for retatrutide are expected to provide more specific information across several key areas. For the type 2 diabetes trials, we anticipate seeing exact percentages of A1C reduction, average weight loss figures, and a detailed list of side effects, including their frequency and severity. Our guide to what the retatrutide trials actually used covers the doses behind these numbers. For the ongoing studies in participants with obesity or who are overweight, similar detailed weight loss results, body composition changes, and safety data will be crucial. We also look for information on the duration of effect, optimal dosing strategies, and how retatrutide performs in comparison to placebo and, potentially, other active comparator drugs. These details are vital for clinicians to make informed decisions about prescribing the medication once it is approved. The more data we have, the clearer the picture becomes regarding retatrutide's overall risk-benefit profile.

The Importance of Ongoing Research

The development of a new drug like retatrutide is a continuous process that extends beyond initial approvals. Lilly's commitment to further research ensures a comprehensive understanding of the medication. This includes long-term safety studies, real-world evidence gathering, and potentially exploring its use in other patient populations or in combination with other therapies. Ongoing research helps to refine our understanding of the drug's benefits and risks over extended periods and in diverse groups of patients. It also contributes to the broader scientific knowledge base, paving the way for future innovations. We emphasize the importance of relying on data from authoritative sources, as the scientific process is designed to be transparent and evidence-based. As the research progresses, new insights will undoubtedly emerge, further shaping the clinical utility of retatrutide.

Staying Informed About Retatrutide

To stay informed about the latest developments regarding retatrutide, we recommend monitoring official sources such as Eli Lilly and Company's investor relations news releases and government-sponsored clinical trial databases like ClinicalTrials.gov. These platforms are the primary channels for accurate and timely information directly from the source. As a specialized publication, The GLP-1 Daily will continue to analyze and report on these updates as they become available, translating complex scientific findings into clear and actionable insights for our readers. Our goal is to keep you abreast of all significant advancements in the GLP-1 medication space, ensuring you have the truth about these life-changing treatments, supported by real data. We are committed to providing updates as new data becomes publicly available from authoritative sources.

Frequently Asked Questions

What is retatrutide?

Retatrutide, known as LY3437943, is an investigational triple agonist medication developed by Eli Lilly and Company. It targets three hormone receptors—GLP-1, GIP, and glucagon—to help manage blood sugar and body weight. This multi-target approach aims to provide comprehensive benefits for conditions like type 2 diabetes and obesity.

What were the key findings for retatrutide in type 2 diabetes trials?

Lilly announced that retatrutide demonstrated significant reductions in A1C and weight in its first Phase 3 trial for the treatment of type 2 diabetes. These findings suggest the drug is effective at both improving blood sugar control and promoting weight loss in this patient population. The results highlight its potential as a powerful new treatment option.

Is retatrutide available for weight loss yet?

No, retatrutide is not yet available for weight loss. It is currently in active Phase 3 clinical trials, including a study specifically for participants who have obesity or are overweight, identified as NCT05929066 on ClinicalTrials.gov. The drug must complete all necessary trials and receive regulatory approval before it can be prescribed to patients.

How does retatrutide differ from orforglipron?

Retatrutide is an injectable triple agonist, meaning it activates GLP-1, GIP, and glucagon receptors. Orforglipron, on the other hand, is an oral GLP-1 receptor agonist, targeting only the GLP-1 pathway and administered as a pill. Both are from Lilly and have shown promising results for weight loss, with orforglipron delivering up to an average of 27.3 lbs weight loss in one pivotal Phase 3 trial.

Where can I find more information about Lilly's clinical trials?

You can find more information about Lilly's clinical trials, including those for retatrutide, on their official clinical trials website at https://trials.lilly.com/en-US/trial/687735. Additionally, detailed study information, such as the trial for retatrutide in obesity, can be found on ClinicalTrials.gov under the identifier NCT05929066. These are authoritative sources for clinical research data.